Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL [SIN16922P]

Active ingredients: TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL

View product's general information
Last updated 24 April 2026

Product Info

TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL

[SIN16922P]

Product information

Active Ingredient and Strength

TREOSULFAN - 5 G/VIAL

Dosage Form

INJECTION, POWDER, FOR SOLUTION

Manufacturer and Country

ONCOTEC PHARMA PRODUKTION GMBH - GERMANY

Registration Number

SIN16922P

Licence Holder

LINK HEALTHCARE SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L01AB02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) at increased risk of toxicity with standard conditioning therapies, and in paediatric patients older than one month with malignant and non-malignant diseases.

Dosing

4.2 Posology and method of administration

Administration of treosulfan should be supervised by a physician experienced in conditioning treatment followed by alloHSCT.

Posology

Adults with AML and MDS

Treosulfan is given in combination with fludarabine.
The recommended dose and schedule of administration is:

  • Treosulfan 10 g/m2 body surface area (BSA) per day as a two-hour intravenous infusion, given on three consecutive days (day -4, -3, -2) before stem cell infusion (day 0). The total treosulfan dose is 30 g/m2;

  • Fludarabine 30 mg/m2 BSA per day as a 0.5-hour intravenous infusion, given on five consecutive days (day -6, -5, -4, -3, -2) before stem cell infusion (day 0). The total fludarabine dose is 150 mg/m2;

  • Treosulfan should be administered before fludarabine on days -4, -3, -2 (FT10 regimen).

Special populations

Paediatric population older than 1 month

Treosulfan is given in combination with fludarabine, with thiotepa (intensified regimen; FT10–14TT regimen) or without thiotepa (FT10–14 regimen).
The recommended dose and schedule of administration is:
• Treosulfan 10–14 g/m2 body surface area (BSA) per day as a two-hour intravenous infusion, given on three consecutive days (day -6, -5, -4) before stem cell infusion (day 0). The total treosulfan dose is 30–42 g/m2;
The dose of treosulfan should be adapted to the patient’s BSA as follows (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information):

Trecondi Dosage Table 1



• Fludarabine 30 mg/m2 BSA per day as a 0.5-hour intravenous infusion, given on five consecutive days (day -7, -6, -5, -4, -3) before stem cell infusion (day 0). The total fludarabine dose is 150 mg/m2;
• Treosulfan should be administered before fludarabine;
• Thiotepa (intensified regimen 5 mg/kg twice a day), given as two intravenous infusions over 2–4 hours on day -2 before stem cell infusion (day 0).

The safety and efficacy of treosulfan in children less than 1 month of age has not yet been established.

Elderly

No dose adjustment is necessary in any subset of the elderly population.

Renal and hepatic impairment

No dose adjustment is necessary for mild or moderate impairment, but treosulfan is contraindicated in patients with severe impairment (see section 4.3).

Method of administration

Treosulfan is for intravenous use as a two-hour infusion.

Precautions to be taken before handling or administering the medicinal product

When handling treosulfan, inhalation, skin contact or contact with mucous membranes should be avoided. Pregnant personnel should be excluded from handling cytotoxics.

Intravenous administration should be performed using a safe technique to avoid extravasation (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

For instructions on reconstitution of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Contraindications

4.3 Contraindications

  • Hypersensitivity to the active substance

  • Active non-controlled infectious disease

  • Severe concomitant cardiac, lung, liver, and renal impairment

  • Fanconi anaemia and other DNA breakage repair disorders

  • Pregnancy (see section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)

  • Administration of live vaccine